Attached files

file filename
EX-99.1 - EX-99.1 - Ocera Therapeutics, Inc.a11-25022_1ex99d1.htm

 

 

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): August 19, 2011

 

TRANZYME, INC.

(Exact name of registrant as specified in its charter)

 

DELAWARE

 

001-35119

 

63-1192270

(State or other jurisdiction of
incorporation)

 

(Commission File Number)

 

(I.R.S. Employer
Identification No.)

 

4819 Emperor Boulevard, Suite 400

Durham, NC

 

27703

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code (919) 313-4760

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On August 19, 2011, Gordana Kosutic, M.D. tendered her resignation as Vice President, Clinical and Regulatory Affairs of Tranzyme, Inc. (the “Company”) effective September 30, 2011. The Company has initiated a formal search for a Chief Medical Officer and has named M. Scott Harris, M.D., a consultant with the Company since June 2010, to act in this capacity until a permanent replacement is appointed. In addition, Philippa Charlton, M.D., the Company’s Medical Director, will assume the day-to-day responsibilities for clinical operations.

 

A copy of the Company’s press release announcing these matters is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.

 

Description

99.1

 

 

Press Release of Tranzyme, Inc. dated August 25, 2011.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: August 25, 2011

Tranzyme, Inc.

 

 

 

By:

/s/ Vipin K. Garg, Ph.D.

 

 

Vipin K. Garg, Ph.D.

 

 

President and Chief Executive Officer

 

3